This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert M. Fine, MD

Arch Dermatol. 1983;119(10):865-868.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is difficult to conceive of practicing dermatology today without access to the clinical use of corticosteroids given for systemic effects, yet these potent antiphlogistic agents have been available for only 30 years. The centennial article by Sulzberger et al introduced these drugs to the clinical dermatologist and began a revolutionary new era of anti-inflammatory therapy for dermatologic disorders.¹ Dermatoses which were previously poorly or completely unresponsive to the available treatment modalities responded, often in a dramatic fashion, to oral cortisone acetate therapy, with or without supplemental corticotrophin. The prescience of these authors was remarkable. In their comprehensive article, they recorded their experience in treating a large series of patients with a variety of dermatoses and tabulated concisely many of the crucial variables needed to assess the efficacy of these new "wonder" drugs, namely, initialand maintenance-dose requirements, response, duration of treatment, and course after stopping medication. In addition, . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Dermatology, Emory University, Atlanta; and the Section of Dermatology, Veterans Administration Hospital, Decatur, Ga.

Footnotes
Accepted for publication March 14, 1983.

Reprint requests to the Winn Way Professional Building, 487 Winn Way, Suite 209, Decatur, GA 30030 (Dr Fine).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?